Overview

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Apexigen, Inc.